Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial

BACKGROUND: Currently, there is no US Food and Drug Administration approved therapy for patients with pleural mesothelioma who have relapsed following platinum-doublet based chemotherapy. Vinorelbine has demonstrated useful clinical activity in mesothelioma, however its efficacy has not been formall...

Descripción completa

Detalles Bibliográficos
Autores principales: Fennell, Dean A., Porter, Catharine, Lester, Jason, Danson, Sarah, Taylor, Paul, Sheaff, Michael, Rudd, Robin M, Gaba, Aarti, Busacca, Sara, Nixon, Lisette, Gardner, Georgina, Darlison, Liz, Poile, Charlotte, Richards, Cathy, Jordan, Peter-Wells, Griffiths, Gareth, Casbard, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124711/
https://www.ncbi.nlm.nih.gov/pubmed/35706488
http://dx.doi.org/10.1016/j.eclinm.2022.101432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124711/
https://www.ncbi.nlm.nih.gov/pubmed/35706488
http://dx.doi.org/10.1016/j.eclinm.2022.101432

Ejemplares similares